Abstract: The present invention discloses an immediate release tablet comprising at least a tablet core, wherein the tablet core comprises at most 20% brexpiprazole relative to the total of the tablet core, and at least one pharmaceutically acceptable excipient, wherein the tablet core is made by direct compression. Also disclosed are a batch of such immediate release tablets, and a process for preparing such immediate release tablets.

Abstract: The present invention relates to crystalline brexpiprazole having a particle size distribution (PSD) characterized by a d(90) of 30 ?m to 100 ?m, by a d(10) of at least 1.0 ?m, and by a d(4,3) of at least 15.0 ?m. The present invention also relates to a pharmaceutical composition comprising a crystalline brexpiprazole having a PSD characterized by a d(90) of 30 ?m to 100 ?m, by a d(10) of at least 1.0 ?m, and by a d(4,3) of at least 15.0 ?m, and to an aqueous suspension comprising said crystalline brexpiprazole. The present invention also relates to a composition comprising a crystalline brexpiprazole having a PSD characterized by a d(90) of 30 ?m to 100 ?m, by a d(10) of at least 1.0 ?m, and by a d(4,3) of at least 15.0 ?m, wherein said composition is essentially free from secondary particles of brexpiprazole.

Abstract: The present invention relates to a pharmaceutical composition comprising linagliptin or a pharmaceutically acceptable salt thereof as active ingredient, wherein the pharmaceutical composition does not comprise a binder and wherein the pharmaceutical composition is obtained by direct compression.

Abstract: The present invention discloses possibilities to make use of a substance or a material arranged to block, absorb and/or reflect UV exposure of a certain wavelength region to reduce or prevent UV-induced dimerization and optionally further UV-induced brexpiprazole impurities of brexpiprazole in a brexpiprazole dihydrate comprising pharmaceutical composition.

Abstract: The present invention discloses an immediate release tablet comprising at least a tablet core, wherein the tablet core comprises at most 20% brexpiprazole relative to the total of the tablet core, and at least one pharmaceutically acceptable excipient, wherein the tablet core is made by direct compression. Also disclosed are a batch of such immediate release tablets, and a process for preparing such immediate release tablets.

Abstract: The present invention relates to crystalline brexpiprazole having a particle size distribution (PSD) characterized by a d(90) of 30 ?m to 100 ?m, by a d(10) of at least 1.0 ?m, and by a d(4,3) of at least 15.0 ?m. The present invention also relates to a pharmaceutical composition comprising a crystalline brexpiprazole having a PSD characterized by a d(90) of 30 ?m to 100 ?m, by a d(10) of at least 1.0 ?m, and by a d(4,3) of at least 15.0 ?m, and to an aqueous suspension comprising said crystalline brexpiprazole. The present invention also relates to a composition comprising a crystalline brexpiprazole having a PSD characterized by a d(90) of 30 ?m to 100 ?m, by a d(10) of at least 1.0 ?m, and by a d(4,3) of at least 15.0 ?m, wherein said composition is essentially free from secondary particles of brexpiprazole.

Abstract: The present invention relates to a solid oral pharmaceutical composition comprising vortioxetine hydrobromide in a matrix formed from at least one polyethylene oxide and optionally one or more further matrix forming polymers.

Abstract: The present invention relates to orodispersible films comprising a plant extract and to film forming suspensions comprising a plant extract. Further, the present invention relates to processes for preparing the orodispersible films and the film forming suspensions.

Abstract: A solid dispersion comprising suvorexant or a salt thereof in amorphous form and at least one pharmaceutically acceptable matrix compound, wherein the matrix compound is (i) a polymer and wherein the solid dispersion contains the suvorexant or salt thereof in an 5 amount of at least 50 weight-% based on the combined weight of the suvorexant or salt thereof and the at least one matrix compound, or (ii) a silicon-based inorganic adsorbent.

Abstract: The present invention relates to a pharmaceutical composition comprising linagliptin or a pharmaceutically acceptable salt thereof as active ingredient, wherein the pharmaceutical composition does not comprise a binder and wherein the pharmaceutical composition is obtained by direct compression.

Abstract: The present invention relates to orodispersible films comprising a plant extract and to film forming suspensions comprising a plant extract. Further, the present invention relates to processes for preparing the orodispersible films and the film forming suspensions.

Abstract: The present invention relates to a solid oral pharmaceutical composition comprising vortioxetine hydrobromide in a matrix formed from at least one polyethylene oxide and optionally one or more further matrix forming polymers.

Abstract: A solid dispersion comprising suvorexant or a salt thereof in amorphous form and at least one pharmaceutically acceptable matrix compound, wherein the matrix compound is (i) a polymer and wherein the solid dispersion contains the suvorexant or salt thereof in an 5 amount of at least 50 weight-% based on the combined weight of the suvorexant or salt thereof and the at least one matrix compound, or (ii) a silicon-based inorganic adsorbent.

Abstract: The present invention relates to pharmaceutical tablets comprising amorphous compound I in the form of its free base or pharmaceutically acceptable salts of compound I.

Abstract: The present invention relates to pharmaceutical tablets comprising amorphous compound I or pharmaceutically acceptable salts thereof, and an inert organic carrier.

Abstract: The present invention relates to an oral pharmaceutical composition comprising dabigatran etexilate or a pharmaceutically acceptable salt thereof, methods for preparing it and dosage forms for oral administration comprising said composition. The pharmaceutical composition is particularly useful as a medicament, especially as anticoagulant.

Abstract: The present invention relates to a sustained-release pharmaceutical formulation, in particular a multiple unit pellet tablet (MUT) formulation for oral administration comprising a plurality of sustained-release pellets. The invention further relates to sustained-release pellets wherein the active agent is an opioid. The sustained-release pellets are suitable for the preparation of a multiple unit pellet tablet formulation.

Abstract: The invention relates to a process for preparing a composition, more particularly a pharmaceutical composition for oral administration, comprising the steps of forming a suspension of at least one pharmaceutical ingredient and a solvent or solvent mixture, the at least one pharmaceutical ingredient being insoluble or poorly soluble in the solvent or solvent mixture, the step of adding at least one gel former to the suspension, the at least one gel former being swellable in the solvent or solvent mixture, and, optionally, the step of swelling the suspension.

Abstract: An oral film comprising 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one base or salts or hydrates thereof.

Abstract: The present invention refers to a dosage form comprising an enteric coating in a specific amount, and to the use of enteric coating compositions for preparing a dosage form. Furthermore, the present invention also relates to a process for the preparation of a solid oral dosage form.